Annual Report 2006

83
During the press conference Prof. Eliezer
Robinson, ICA Chairman, gave a brief overview
of ICA's impressive achievements and the next
targets that the association has set for itself for
the coming year.
Israel Makov, Teva CEO, was appointed ICA
"Door Knock Campaign" Chairman for 2005. At
the campaign launching held at the Presidential
Residence (see below), Makov announced that
Teva would donate one million shekels to the ICA
for cancer research in Israel through fellowships
for outstanding Israeli researchers who will be
selected by the ICA Research Committee. A
sum of one million shekels was presented to
ICA Director General, Mrs. Miri Ziv; said Makov:
"Our investments in cancer research are steadily
increasing and will amount to a total of 100-130
million shekels this coming year. The objective
is to develop better drugs for treating the disease,
because today's research is tomorrow's
treatment." Makov called upon the State to
prioritize the increase in funding future projects
and outstanding Israeli researchers in general,
and in the field of cancer in particular, in order to
make it easier for patients and their families and
to add to Israel's scientific strength. Additional
corporate companies and the Israeli public must
join the ranks and contribute generously to the
"Door Knock" fundraising campaign.
Mrs. Miri Ziv. ICA Director General, said that
the donations that would be collected during the
"Door Knock" fundraising campaign would enable
the ICA to finance dozens of research studies of
physicians and scientists who are endeavoring
to find a cure for the disease, and would also
assist in conducting educational activities in
order to increase cancer awareness among the
general population, in addition to initiating and
establishing national early detection programs for
various different cancers which when detected
early have a higher chance of being cured, to
financially support cancer patients in need, to
assist children who have cancer in completing
their studies, to run summer camps for child
cancer patients and their families, to purchase
state of the art medical equipment for medical
centers treating cancer patients, to establish
departments for cancer patients in hospitals
throughout the country, to finance the employment
of nurses and social workers who assist
cancer patients at hospitals and in community
clinics and to endeavor for the welfare of cancer
patients in Israel.
During the press conference the ICA published
a special annual report on the total cost of its
investments in the war against cancer throughout
the year, and released discoveries and research
data relating to the fight against cancer.
Teva Pharmaceuticals
contributes one million
shekels to cancer
research in Israel
Teva's contribution was provided through
fellowships for outstanding researchers to
be selected by the ICA Research Committee.
Israel Makov, Teva CEO and
"Door Knock" Campaign Chairman
said that "today's research is tomorrow's
treatment" upon presenting the cheque
and called upon corporate companies
and the Israeli public to join the ranks and
contribute generously to the campaign.
"I believe that together we can reinforce
Israeli research excellence and bring a cure
to this dreadful disease", said Makov.
Miri Ziv ICA Director General and Israel Makov, Teva CEO
and ICA "Door Knock" Campaign Chairman for 2005.
Photographer: Israel Hadari.